AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$CADL

Tak Paul Peter sold $3.2M of CADL

Tak Paul Peter (Chief Executive Officer) sold 280,245 shares of Candel Therapeutics, Inc. (CADL) at an average of $11.28 ($10.46–$11.50, $3.16M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tak Paul Peter
Published Sep 11, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CADL
Bearish
medium confidence
Mentioned
$CADL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CADLBearishLow
01

Why it matters

The sale reduces insider ownership, which some investors view as a negative signal, though the pre‑arranged plan tempers interpretation.

02

Market read

Primary relevance is to CADL shareholders; broader market impact is negligible.

03

What to watch

CEO's 10b5‑1 plan pre‑arranged; could mask lack of confidence.

Relevance 5/10Novelty 4/10Timing: filing date 2026-09-11

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on executive holdings.

Company-level read

Ticker impact

$CADLBearishMedium confidence
Context

CEO Tak Paul Peter sold 280,245 shares for $3.16M via a 10b5‑1 plan, reducing his stake to 113,321 shares.

Expected impact

Modest downward pressure, likely 1‑2% dip if market reacts.

Evidence & confidence

Insider sale of this size by the CEO suggests possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No significant regional effect.

Global

Limited to investors tracking CADL.

Counterpoint

What could challenge this read

Sale may be routine liquidity need; not necessarily bearish.

Key entities

  • Company
    Candel Therapeutics, Inc.

    Biotech firm developing therapies; ticker CADL.

  • Person
    Tak Paul Peter

    CEO and Director of Candel Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CADL insider trading history →

Related articles

OCT 1
$CADLMedAI 8/10

Candel's Aglatimagene Shows Prolonged Survival In Phase 2a NSCLC Trial

Candel Therapeutics (CADL) reported Phase 2a trial results for aglatimagene in NSCLC patients. Median overall survival was 24.5 months in the evaluable population. The treatment showed systemic immune responses and was generally well tolerated. Candel is advancing to a Phase 3 trial. CADL stock is currently at $10.39, down 0.67%.

rttnews.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026

Candel Therapeutics (CADL) presented data at ASTRO 2026 showing aglatimagene besadenovec significantly increased immune response in prostate cancer patients over two years. The phase 3 trial showed 80% of aglatimagene patients had negative biopsies vs. 63% of controls. The company plans to submit a BLA based on these results.

globenewswire.com2 min
SEP 21
$CADLHigh

Why is Candel Therapeutics stock surging today?

Candel Therapeutics (CADL) stock rose 7.2% to $11.63 after Bank of America upgraded it to Buy with an $18.00 price target, up from $12.00. The company has 8 Buy ratings, 1 Hold, and no Sell recommendations. Its lead therapy targets a $10–16B prostate cancer market. The Nasdaq and S&P 500 also gained 1.1% and 0.7%, respectively.

investing.com1 min